InsidersTradesSigma
Clover Health Investments, CORP. /de Stock: price and insider trades · United States · SEC (Form 4)
Track the Clover Health Investments, CORP. /de stock price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Clover Health Investments, CORP. /de has recorded 251 public disclosures. Market capitalisation: €2.8bn. The latest transaction was reported on 1 July 2026 (Cession). Among the most active insiders: Reynoso Jamie L.. All data is free.
251
Insider Decl.
0
Thresholds
€4m
9 ops.
Buy Volume
€2m
22 ops.
Sell Volume
39Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 22,911 of 25,484 companies
22.2
score / 100
Value26
Quality19
FCF yld-2.5%
Earn yld-3.1%
EV/EBITDA·
ROE-17%
Gross mgn18%
Net mgn-4.4%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 1 July 2026
Declarations251 total
313,476 sharesClass A Common StockSEC:0001838733-26-000015:0
2,360 sharesClass A Common StockSEC:0001839066-26-000024:0
12,102 sharesClass A Common StockSEC:0001801170-26-000161:0
4,681 sharesClass A Common StockSEC:0001801170-26-000151:0
6,350 sharesClass A Common StockSEC:0001839066-26-000022:0
7,289 sharesClass A Common StockSEC:0001839066-26-000017:0
220,426 shares@ US$3.990.040% mcap25.6% of flowClass A Common StockSEC:0001971702-26-000010:0
85,704 shares@ US$2.820.017% mcap4.3% of flowClass A Common StockSEC:0001801170-26-000123:0
85,704 shares@ US$2.820.011% mcap4.3% of flowClass A Common StockSEC:0001801170-26-000123
36,113 shares@ US$2.190.0035% mcap7.5% of flowClass A Common StockSEC:0001801170-26-000090
36,113 shares@ US$2.190.0055% mcap7.5% of flowClass A Common StockSEC:0001801170-26-000090:0
60,765 shares@ US$2.040.0056% mcap2.2% of flowClass A Common StockSEC:0001838733-26-000012
12,712 shares@ US$2.040.0012% mcap1.6% of flowClass A Common StockSEC:0001839066-26-000015
23,463 shares@ US$2.040.0021% mcap6.2% of flowClass A Common StockSEC:0001971702-26-000007
15,471 shares@ US$2.040.0014% mcap3.0% of flowClass A Common StockSEC:0001938197-26-000008
10,161 shares@ US$2.040.0009% mcap4.8% of flowClass A Common StockSEC:0001999086-26-000012
10,161 shares@ US$2.040.0014% mcap4.8% of flowClass A Common StockSEC:0001999086-26-000012:0
23,463 shares@ US$2.040.0033% mcap6.2% of flowClass A Common StockSEC:0001971702-26-000007:0
12,712 shares@ US$2.040.0018% mcap1.6% of flowClass A Common StockSEC:0001839066-26-000015:0
60,765 shares@ US$2.040.0086% mcap2.2% of flowClass A Common StockSEC:0001838733-26-000012:0
15,471 shares@ US$2.040.0022% mcap3.0% of flowClass A Common StockSEC:0001938197-26-000008:0
6,197 shares@ US$1.720.0005% mcap0.4% of flowClass A Common StockSEC:0001839066-26-000014:0
85,704 shares@ US$2.133.2% of flowClass A Common StockSEC:0001838733-26-000007
85,704 shares@ US$2.130.013% mcap3.2% of flowClass A Common StockSEC:0001838733-26-000007:0
11,686 shares@ US$2.810.0023% mcap7.7% of flowClass A Common StockSEC:0001801170-26-000026:0
25 of 251 declarations
About Clover Health Investments, CORP. /de
Clover Health Investments, Corp. is a United States healthcare company listed on NASDAQ, focused on Medicare Advantage insurance and clinical decision-support technology. The company traces its public-market origin to 2019, when it was formed as a SPAC under the name Social Capital Hedosophia Holdings Corp. III, and it completed its business combination with Clover Health in January 2021. Clover describes itself as a remote-first company and does not maintain a traditional headquarters, although its principal executive office communications are handled through Jersey City, New Jersey. The core business is its Insurance segment, which offers Medicare Advantage PPO and HMO plans to eligible seniors across several U.S. states. Clover’s competitive proposition is built around Clover Assistant, a proprietary technology platform designed to bring more actionable clinical information into the physician workflow. The system synthesizes claims, chart, medication, diagnostic, and EHR data to help providers identify chronic conditions earlier, close care gaps, and improve disease management. In practice, Clover is not simply an insurer; it aims to use software and data to influence utilization, quality outcomes, and medical cost trend. From a positioning standpoint, Clover competes in the highly contested Medicare Advantage market, where scale, pricing discipline, provider relationships, and CMS quality scores matter materially. The company emphasizes wide-network PPO products and technology-enabled care management as differentiators, particularly in markets where traditional integrated-provider models are less dominant. That technology layer is central to Clover’s strategy because it provides a path to support member retention, improve cohort economics, and potentially widen margins over time. A key strategic extension is Counterpart Health, launched as a SaaS and tech-enabled services offering to commercialize Clover Assistant for external payors and providers serving the Medicare-eligible population. This gives Clover an additional growth avenue beyond its own insurance book, with the potential for higher-margin software-style economics if adoption scales. Recent developments have been important. In late February 2026, Clover reported full-year 2025 results showing strong revenue growth, continued membership expansion, and positive adjusted EBITDA for the year. Management also guided to potential full-year 2026 GAAP net income profitability, which is a notable milestone for an insurance-tech platform that has historically focused on scaling first and profits later. At the same time, investors should watch regulatory and reimbursement sensitivity, especially Medicare rate updates, CMS Star ratings, and the company’s ability to sustain Clover Assistant adoption and medical cost control.
